Eli Lilly Raises 2024 Full-year Revenue Guidance By $3B To $45.4B-$46.6B, Primarily Driven By The Strong Performance Of Mounjaro And Zepbound, As Well As The Company's Non-incretin Medicines, Compared To Consensus Of $43.026B
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has raised its 2024 full-year revenue guidance by $3 billion to a range of $45.4 billion to $46.6 billion, driven by strong performance of Mounjaro and Zepbound, as well as non-incretin medicines. The company has also improved clarity on production expansions and planned Mounjaro launches outside the U.S.
August 08, 2024 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly has raised its 2024 revenue guidance by $3 billion, driven by strong performance of key drugs and improved production clarity.
The increase in revenue guidance by $3 billion is a significant positive indicator for Eli Lilly, driven by strong performance of key drugs and improved production clarity. This is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100